Livzon Pharmaceutical Group Inc.

000513.SZ

000513.SZLivzon Pharmaceutical Group Inc.

Shenzhen

35.30

CNY

-0.40

(-1.12%)

2.15EPS

16.42P/E

29.18BMarket Cap

Oct 22Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Livzon Pharmaceutical Group Inc.

000513.SZ

(Shenzhen)

Recent

price

35.30

P/E

ratio

16.42

div

yld

3.82%

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 09/15

Stock

S&P500

-0.98

26.76

-10.61

25.48

26.98

87.24

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
2.35	3.04	3.22	3.76	4.66	5.47	6.55	7.84	8.77	9.22	9.5	10.01	11.23	12.91	13.49	13.36	12.86	Revenue per Share
0.06	0.56	0.49	0.43	0.52	0.58	0.61	0.74	0.9	4.78	1.16	1.39	1.83	1.9	2.04	2.1	2.13	Basic EPS, GAAP
0.31	0.43	0.35	0.43	-0.2	-0.57	0.06	0.53	1.04	1.1	0.85	1.46	1.62	0.63	1.96	2.61	-0.74	Free Cash Flow per Basic Share
0.22	0.06	0.07	0.04	0.22	0.23	0.24	0.1	0.27	0.23	1.2	0.93	1.17	1.35	1.39	1.71	1.44	Dividend per Share
1.16	1.65	2.06	2.42	2.74	3.14	3.55	4.34	4.86	9.28	9.36	9.98	10.55	11.4	12.15	12.72	12.57	Book Value per Share
1.8	2.3	2.8	3.25	3.39	3.88	4.4	5.25	7.67	11.71	12.14	12.58	13.92	14.31	14.96	14.97	14.71	Tangible Book Value per Share
875	854	847	841	847	844	846	844	872	926	933	937	937	935	936	930	935	Basic Weighted Avg Shares
2,059	2,596	2,727	3,163	3,944	4,619	5,544	6,621	7,652	8,531	8,861	9,385	10,520	12,064	12,630	12,430	12,022	Sales/Revenue/Turnover
17.62	22.16	18.98	14.41	13.35	13.37	11.89	12.33	12.92	14.2	12.47	16.89	22	18.13	17.69	19.56	21.44	Operating Margin (%)
132	127	121	141	152	169	247	311	362	359	364	385	394	445	652	840	- -	Depreciation Expense
52	482	418	359	442	488	516	623	784	4,429	1,082	1,303	1,715	1,776	1,909	1,954	1,990	Net Income, GAAP
30.99	12.83	15.21	16.27	15.19	16.69	15.09	18.36	17.43	21.61	16.59	15.4	14.39	13.07	16.09	20.36	19.06	Effective Tax Rate (%)
2.53	18.55	15.34	11.36	11.2	10.56	9.31	9.4	10.25	51.91	12.21	13.88	16.3	14.72	15.12	15.72	16.55	Profit Margin (%)
642	1,064	1,231	1,387	598	651	497	423	2,660	6,949	7,102	7,580	8,544	7,748	9,591	9,179	7,810	Working Capital
101	91	67	1	1	550	466	1	1	1	1	- -	370	642	1,986	1,622	722	LT Debt
1,835	2,225	2,639	3,012	3,180	3,605	4,082	4,810	7,106	11,234	11,750	12,275	13,640	14,311	14,936	14,767	14,607	Total Equity
9.93	19.64	15.59	12	12.6	12.19	11.7	12.8	12.73	9.74	7.19	9.84	13.4	11.56	10.45	10.21	11.1	Return on Invested Capital (%)
3.66	26.53	19.63	14.98	15.41	13.14	12.25	13.57	15.83	62.95	9.78	9.94	10.49	11.94	12.67	12.77	12.16	Return on Capital (%)
4.87	39.67	26.53	19.02	20.28	19.63	18.26	18.68	19.85	69.05	12.5	14.41	17.83	17.29	17.34	16.84	17.47	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	10.62%	7.16%	-1.58%
Net Income, GAAP	50.7%	13.08%	2.32%
Free Cash Flow	101.36%	52.76%	32.52%
Total Cash Common Dividend	57.85%	8.82%	22.28%
Total Equity	16.52%	4.75%	-1.14%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.

	Dec'23	Mar'24	Jun'24
ST Debt	2,520	2,700	3,316
LT Borrowings	1,613	857	714
LT Finance Leases	9	8	8
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	924	927	926
Market Capitalization	31,677	32,907	33,543

	Dec'23	Mar'24	Jun'24
Total Current Assets	17,266	17,178	17,507
Accounts Receivable, Net	2,116	2,067	2,348
Cash, Cash Equivalents & STI	11,408	11,231	11,566
Inventories	2,061	2,015	1,974
Total Current Liabilities	8,087	8,330	9,697
Payables & Accruals	- -	- -	- -
ST Debt	2,520	2,700	3,316
Deferred Revenue	- -	- -	- -

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
2.35	3.04	3.22	3.76	4.66	5.47	6.55	7.84	8.77	9.22	9.5	10.01	11.23	12.91	13.49	13.36	12.86	Revenue per Share
0.06	0.56	0.49	0.43	0.52	0.58	0.61	0.74	0.9	4.78	1.16	1.39	1.83	1.9	2.04	2.1	2.13	Basic EPS, GAAP
0.31	0.43	0.35	0.43	-0.2	-0.57	0.06	0.53	1.04	1.1	0.85	1.46	1.62	0.63	1.96	2.61	-0.74	Free Cash Flow per Basic Share
0.22	0.06	0.07	0.04	0.22	0.23	0.24	0.1	0.27	0.23	1.2	0.93	1.17	1.35	1.39	1.71	1.44	Dividend per Share
1.16	1.65	2.06	2.42	2.74	3.14	3.55	4.34	4.86	9.28	9.36	9.98	10.55	11.4	12.15	12.72	12.57	Book Value per Share
1.8	2.3	2.8	3.25	3.39	3.88	4.4	5.25	7.67	11.71	12.14	12.58	13.92	14.31	14.96	14.97	14.71	Tangible Book Value per Share
875	854	847	841	847	844	846	844	872	926	933	937	937	935	936	930	935	Basic Weighted Avg Shares
2,059	2,596	2,727	3,163	3,944	4,619	5,544	6,621	7,652	8,531	8,861	9,385	10,520	12,064	12,630	12,430	12,022	Sales/Revenue/Turnover
17.62	22.16	18.98	14.41	13.35	13.37	11.89	12.33	12.92	14.2	12.47	16.89	22	18.13	17.69	19.56	21.44	Operating Margin (%)
132	127	121	141	152	169	247	311	362	359	364	385	394	445	652	840	- -	Depreciation Expense
52	482	418	359	442	488	516	623	784	4,429	1,082	1,303	1,715	1,776	1,909	1,954	1,990	Net Income, GAAP
30.99	12.83	15.21	16.27	15.19	16.69	15.09	18.36	17.43	21.61	16.59	15.4	14.39	13.07	16.09	20.36	19.06	Effective Tax Rate (%)
2.53	18.55	15.34	11.36	11.2	10.56	9.31	9.4	10.25	51.91	12.21	13.88	16.3	14.72	15.12	15.72	16.55	Profit Margin (%)
642	1,064	1,231	1,387	598	651	497	423	2,660	6,949	7,102	7,580	8,544	7,748	9,591	9,179	7,810	Working Capital
101	91	67	1	1	550	466	1	1	1	1	- -	370	642	1,986	1,622	722	LT Debt
1,835	2,225	2,639	3,012	3,180	3,605	4,082	4,810	7,106	11,234	11,750	12,275	13,640	14,311	14,936	14,767	14,607	Total Equity
9.93	19.64	15.59	12	12.6	12.19	11.7	12.8	12.73	9.74	7.19	9.84	13.4	11.56	10.45	10.21	11.1	Return on Invested Capital (%)
3.66	26.53	19.63	14.98	15.41	13.14	12.25	13.57	15.83	62.95	9.78	9.94	10.49	11.94	12.67	12.77	12.16	Return on Capital (%)
4.87	39.67	26.53	19.02	20.28	19.63	18.26	18.68	19.85	69.05	12.5	14.41	17.83	17.29	17.34	16.84	17.47	Return on Common Equity (%)

Year	Q1	Q2	Q3	Q4	FY
2022	3,479	2,824	3,186	3,141	12,630
2023	3,413	3,277	2,965	2,775	12,430
2024	3,243	3,040	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	0.59	- -	- -	- -	2.04
2023	0.62	- -	- -	- -	2.1
2024	0.65	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	0.02	- -	- -	- -	1.39
2023	0.03	- -	- -	- -	1.71
2024	0.02	- -	- -	- -	- -

Livzon Pharmaceutical Group Inc.

Growth Rates

(avg. rate of change)

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year